OBJECTIVES: We describe the outcomes of second-line drug resistance profiles and predict the efficacy of drugs for third-line therapy in patients monitored without the benefit of plasma HIV-1 RNA viral load (VL) or resistance testing. METHODS: We recruited 106 HIV-1-infected patients after second-line treatment failure in Mali. VL was determined by the Abbott RealTime system and the resistance by the ViroSeq HIV-1 genotyping system. The resistance testing was interpreted using the latest version of the Stanford algorithm. RESULTS: Among the 106 patients, 93 had isolates successfully sequenced. The median age, VL and CD4 cells were respectively 35 years, 72 000 copies/mL and 146 cells/mm(3). Patients were exposed to a median of 4 years of treatment and to six antiretrovirals. We found 20% of wild-type viruses. Resistance to etravirine was noted in 38%, to lopinavir in 25% and to darunavir in 12%. The duration of prior nucleos(t)ide reverse transcriptase inhibitor exposure was associated with resistance to abacavir (P < 0.0001) and tenofovir (P = 0.0001), and duration of prior protease inhibitor treatment with resistance to lopinavir (P < 0.0001) and darunavir (P = 0.06). CONCLUSION: Long duration of therapy prior to failure was associated with high levels of resistance and is directly related to limited access to VL monitoring and delayed switches to second-line treatment, precluding efficacy of drugs for third-line therapy. This study underlines the need for governments and public health organizations to recommend the use of VL monitoring and also the availability of darunavir and raltegravir for third-line therapies in the context of limited-resource settings.
OBJECTIVES: We describe the outcomes of second-line drug resistance profiles and predict the efficacy of drugs for third-line therapy in patients monitored without the benefit of plasma HIV-1 RNA viral load (VL) or resistance testing. METHODS: We recruited 106 HIV-1-infectedpatients after second-line treatment failure in Mali. VL was determined by the Abbott RealTime system and the resistance by the ViroSeq HIV-1 genotyping system. The resistance testing was interpreted using the latest version of the Stanford algorithm. RESULTS: Among the 106 patients, 93 had isolates successfully sequenced. The median age, VL and CD4 cells were respectively 35 years, 72 000 copies/mL and 146 cells/mm(3). Patients were exposed to a median of 4 years of treatment and to six antiretrovirals. We found 20% of wild-type viruses. Resistance to etravirine was noted in 38%, to lopinavir in 25% and to darunavir in 12%. The duration of prior nucleos(t)ide reverse transcriptase inhibitor exposure was associated with resistance to abacavir (P < 0.0001) and tenofovir (P = 0.0001), and duration of prior protease inhibitor treatment with resistance to lopinavir (P < 0.0001) and darunavir (P = 0.06). CONCLUSION: Long duration of therapy prior to failure was associated with high levels of resistance and is directly related to limited access to VL monitoring and delayed switches to second-line treatment, precluding efficacy of drugs for third-line therapy. This study underlines the need for governments and public health organizations to recommend the use of VL monitoring and also the availability of darunavir and raltegravir for third-line therapies in the context of limited-resource settings.
Authors: Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Thomas P Young; Neil T Parkin; Eric Stawiski; Tami Pilot-Matias; Roger Trinh; Dale J Kempf; Michael Norton Journal: Antimicrob Agents Chemother Date: 2010-08-30 Impact factor: 5.191
Authors: Soo-Yon Rhee; Jonathan Taylor; W Jeffrey Fessel; David Kaufman; William Towner; Paolo Troia; Peter Ruane; James Hellinger; Vivian Shirvani; Andrew Zolopa; Robert W Shafer Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191
Authors: M C Hosseinipour; J J Kumwenda; R Weigel; L B Brown; D Mzinganjira; B Mhango; J J Eron; S Phiri; J J van Oosterhout Journal: HIV Med Date: 2010-03-19 Impact factor: 3.180
Authors: Constance Delaugerre; Philippe Flandre; Marie Laure Chaix; Jade Ghosn; François Raffi; Pierre Dellamonica; H Jaeger; D Shürmann; Isabelle Cohen-Codar; Philippe Ngo Van; Michael Norton; Anne-Marie Taburet; Jean-François Delfraissy; Christine Rouzioux Journal: Antimicrob Agents Chemother Date: 2009-05-18 Impact factor: 5.191
Authors: Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: J Ross; A Jiamsakul; N Kumarasamy; I Azwa; T P Merati; C D Do; M P Lee; P S Ly; E Yunihastuti; K V Nguyen; R Ditangco; O T Ng; J Y Choi; S Oka; A H Sohn; M Law Journal: HIV Med Date: 2020-11-05 Impact factor: 3.180
Authors: Theresa M Rossouw; Ute D Feucht; George Melikian; Gisela van Dyk; Winifred Thomas; Nicolette M du Plessis; Theunis Avenant Journal: PLoS One Date: 2015-07-21 Impact factor: 3.240
Authors: Awachana Jiamsakul; Somnuek Sungkanuparph; Matthew Law; Rami Kantor; Jutarat Praparattanapan; Patrick C K Li; Praphan Phanuphak; Tuti Merati; Winai Ratanasuwan; Christopher K C Lee; Rossana Ditangco; Mahiran Mustafa; Thida Singtoroj; Sasisopin Kiertiburanakul Journal: J Int AIDS Soc Date: 2014-08-19 Impact factor: 5.396
Authors: Holly E Rawizza; Beth Chaplin; Seema T Meloni; Kristin M Darin; Oluremi Olaitan; Kimberly K Scarsi; Chika K Onwuamah; Rosemary A Audu; Philippe R Chebu; Godwin E Imade; Prosper Okonkwo; Phyllis J Kanki Journal: PLoS One Date: 2013-09-17 Impact factor: 3.240
Authors: Vu Phuong Thao; Vo Minh Quang; Jeremy N Day; Nguyen Tran Chinh; Cecilia M Shikuma; Jeremy Farrar; Nguyen Van Vinh Chau; Guy E Thwaites; Sarah J Dunstan; Thuy Le Journal: J Antimicrob Chemother Date: 2015-12-11 Impact factor: 5.790